Evidence map›Paper›PMID 25116105›Full record

ReviewCurrent topics in microbiology and immunology2014

Human FcR polymorphism and disease.

Xinrui Li, Andrew W Gibson, Robert P Kimberly

Abstract readReview
In one paragraph

Review in Current topics in microbiology and immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Evidence for Extensive Duplication and Subfunctionalization ofInternational journal of molecular sciences · 2023
    Article
  8. Article
  9. Article
  10. Role ofFrontiers in immunology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. The Dual Targeting of FcRn and FcγRsFrontiers in immunology · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinrui LiDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Andrew W Gibson
Robert P Kimberly

Funding

Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
NIAMS NIH HHS P01 AR049084
6 · The paper itself

Abstract

Fc receptors play a central role in maintaining the homeostatic balance in the immune system. Our knowledge of the structure and function of these receptors and their naturally occurring polymorphisms, including single nucleotide polymorphisms and/or copy number variations, continues to expand. Through studies of their impact on human biology and clinical phenotype, the contributions of these variants to the pathogenesis, progression, and/or treatment outcome of many diseases that involve immunoglobulin have become evident. They affect susceptibility to bacterial and viral pathogens, constitute as risk factors for IgG or IgE mediated inflammatory diseases, and impact the development of many autoimmune conditions. In this chapter, we will provide an overview of these genetic variations in classical FcγRs, FcRLs, and other Fc receptors, as well as challenges in achieving an accurate and comprehensive understanding of the FcR polymorphisms and genomic architecture.

Indexed as

DNA Copy Number VariationsPolymorphism, Single NucleotideAutoimmune DiseasesHumansHypersensitivityInfectionsInflammationReceptors, FcReceptors, Fc

Identifiers

PMID25116105
PMCPMC4209745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.